Copyright
©The Author(s) 2018.
World J Gastroenterol. Dec 14, 2018; 24(46): 5288-5296
Published online Dec 14, 2018. doi: 10.3748/wjg.v24.i46.5288
Published online Dec 14, 2018. doi: 10.3748/wjg.v24.i46.5288
Table 2 Comparison of efficacy and loss of efficacy in both groups
| Infliximab original Group | 95%CI | CT-P13 Group | 95%CI | P value | Rate difference (95%CI) | |
| Basal global remission | 76/98 (77.6%) | 66.8-86.3 | 81/98 (82.7%) | 74.6-90.7 | 0.474 | -0.173-0.071 |
| Global remission 12 mo | 66/93 (71%) | 61.2-80.7 | 60/88 (68.2%) | 51.1-71.4 | 0.806 | -0.117-0.173 |
| Basal remission CD | 51/67 (76.1%) | 65.2-87.1 | 56/67 (83.6%) | 73.9-93.2 | 0.389 | -0.225-0.076 |
| Remission 12 mo CD | 45/65 (69.2%) | 57.2-81.2 | 42/62 (67.7%) | 55.3-80.2 | 0.992 | -0.163-0.192 |
| Basal UC remission | 25/31 (80.6%) | 62.5-92.5 | 25/31 (80.6%) | 62.5-92.5 | 0.748 | -0.29-0.229 |
| Remission 12 mo UC | 21/28 (75%) | 57.2-92.8 | 18/26 (69.2%) | 49.6-88.9 | 0.866 | -0.219-0.334 |
- Citation: Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldan A, Perea Amarillo R, Merino Bohórquez V, Calleja MA, Caunedo Álvarez Á, Vilches Arenas Á. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol 2018; 24(46): 5288-5296
- URL: https://www.wjgnet.com/1007-9327/full/v24/i46/5288.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i46.5288